                      Corniche Group Incorporated Announces
              Appointment of Mark Weinreb as new President and CEO


New York, NY, February 12, 2003. Corniche Group Incorporated (OTCBB: CNGI) today
announced  the  appointment  of Mark Weinreb as its President and CEO. This move
signals a strategic  change of direction  for the Company  following the closure
last year of its  online  extended  warranty  business,  warrantysuperstore.com.
Under Mark  Weinreb's  direction  the Company  will now be focused on building a
business in the medical sector.

The  Company  will seek to exploit  value from assets and  opportunities  in the
medical sector by acquiring or  participating  in biotech and medical  companies
and technologies.  The Company will focus on new technology developments and may
participate,  or acquire,  the rights to new drugs and medical devices currently
under  development  by  smaller  independent  Biotechnology  companies,  medical
institutions and medical researchers.

Commenting on his  appointment  Mark Weinreb said, "I am very excited about this
opportunity.  The market for medical device  innovation and new drug development
is both huge and fragmented. Right now there appears to be significant potential
to acquire  rights,  interests  and  royalty  streams on  advantageous  terms in
interesting projects."

He  continued,  "We are  currently  in the  process of  putting  together a high
caliber  management team and advisory board drawn from the relevant  disciplines
to assist the Company in the execution of its business model."

Mr.  Weinreb,  age 49,  has many  years of  experience  with  medical  services,
equipment and operations,  as well as with development  stage private and public
companies. Prior to joining Corniche he served as the Chief Executive Officer of
a software  development company pioneering gesture recognition and control using
proprietary inter-active video technology.

To secure  Mr.  Weinreb's  service as  President  and Chief  Executive  Officer,
Corniche has entered into a three-year  employment  agreement with Mr.  Weinreb,
and granted him the right and option,  exercisable  for 10 years, to purchase up
to 2,500,000 shares of Corniche's common stock at an exercise price of $0.03 per
share.


                                    * * * * *

This  release  contains  forward-looking  statements  made  pursuant to the safe
harbor  provisions  of the  Private  Securities  Litigation  Reform Act of 1995.
Forward-looking  statements  represent  management's  judgment  regarding future
events.  Although  management  believes that the expectations  reflected in such
statements are reasonable,  they give no assurance that such  expectations  will
prove to be correct and you should be aware that  actual  results  could  differ
materially  from those  contained  in the  forward-looking  statements  due to a
number of factors.  These  factors  include  the risk that the  Company  will be
unable to raise capital,  to enter successfully the biotech or medical business,
to hire appropriate personnel, or the risks inherent in any new business venture
or those  detailed in Corniche's  reports filed with the Securities and Exchange
Commission.   Corniche   undertakes  no  obligation  to  update  or  revise  the
information  contained in this release  whether as a result of new  information,
future events or circumstances or otherwise.

For further information please contact:

Mark Weinreb on (516) 496 3053


